Acorda Therapeutics Total Assets 2010-2022 | ACOR
Acorda Therapeutics total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Acorda Therapeutics Annual Total Assets
(Millions of US $) |
| 2022 |
$396 |
| 2021 |
$455 |
| 2020 |
$633 |
| 2019 |
$800 |
| 2018 |
$1,300 |
| 2017 |
$1,198 |
| 2016 |
$1,342 |
| 2015 |
$1,111 |
| 2014 |
$1,065 |
| 2013 |
$607 |
| 2012 |
$565 |
| 2011 |
$379 |
| 2010 |
$342 |
| 2009 |
$319 |
Acorda Therapeutics Quarterly Total Assets
(Millions of US $) |
| 2022-12-31 |
$396 |
| 2022-09-30 |
$393 |
| 2022-06-30 |
$406 |
| 2022-03-31 |
$424 |
| 2021-12-31 |
$455 |
| 2021-09-30 |
$466 |
| 2021-06-30 |
$491 |
| 2021-03-31 |
$584 |
| 2020-12-31 |
$633 |
| 2020-09-30 |
$710 |
| 2020-06-30 |
$728 |
| 2020-03-31 |
$754 |
| 2019-12-31 |
$800 |
| 2019-09-30 |
$880 |
| 2019-06-30 |
$1,197 |
| 2019-03-31 |
$1,234 |
| 2018-12-31 |
$1,300 |
| 2018-09-30 |
$1,311 |
| 2018-06-30 |
$1,251 |
| 2018-03-31 |
$1,187 |
| 2017-12-31 |
$1,198 |
| 2017-09-30 |
$1,345 |
| 2017-06-30 |
$1,332 |
| 2017-03-31 |
$1,320 |
| 2016-12-31 |
$1,342 |
| 2016-09-30 |
$1,318 |
| 2016-06-30 |
$1,347 |
| 2016-03-31 |
$1,212 |
| 2015-12-31 |
$1,111 |
| 2015-09-30 |
$1,100 |
| 2015-06-30 |
$1,101 |
| 2015-03-31 |
$1,099 |
| 2014-12-31 |
$1,065 |
| 2014-09-30 |
$973 |
| 2014-06-30 |
$943 |
| 2014-03-31 |
$612 |
| 2013-12-31 |
$607 |
| 2013-09-30 |
$587 |
| 2013-06-30 |
$576 |
| 2013-03-31 |
$565 |
| 2012-12-31 |
$565 |
| 2012-09-30 |
$410 |
| 2012-06-30 |
$403 |
| 2012-03-31 |
$386 |
| 2011-12-31 |
$379 |
| 2011-09-30 |
$351 |
| 2011-06-30 |
$336 |
| 2011-03-31 |
$336 |
| 2010-12-31 |
$342 |
| 2010-09-30 |
$331 |
| 2010-06-30 |
$296 |
| 2010-03-31 |
$318 |
| 2009-12-31 |
$319 |
| 2009-09-30 |
$338 |
| 2009-06-30 |
$368 |
| 2009-03-31 |
$262 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.014B |
$0.119B |
|
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
|
